Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • rainbow over text: 'thank you NHS'
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Rize ICAV Medical Cannabis & Life Sciences UCITS ETF GBP (FLWG)

Sell:420.95p Buy:423.25p 0 Change: 4.80p (1.12%)
Market closed Prices as at close on 5 June 2020 Prices delayed by at least 15 minutes | Switch to live prices |
Change: 4.80p (1.12%)
Market closed Prices as at close on 5 June 2020 Prices delayed by at least 15 minutes | Switch to live prices |
Change: 4.80p (1.12%)
Market closed Prices as at close on 5 June 2020 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.
Trade high:
Year high:
Market Listing:
Previous close:
Trade low:
Year low:
4.10p (0.95%)
Dividend yield:
Data delayed by at least 15 minutes.

ETP Basics

Issuer: Rize UCITS ICAV
Structure: ETF
Replication method: Stocks - Full Replication
Securities lending: No
Number of holdings: 27
Size: $1M
Launch date: 12 February 2020
Launch price: $5.04
Reporting status: Yes
Domicile: Ireland
Sophisticated product: Non-sophisticated

Annual & interim reports

Before you invest, please make sure you read the documents below

Ready to invest?

To buy shares in , you'll need to have an account. Try our handy filter to explore the different options.

Compare accounts

Ready to take your first step?

To invest in , you'll need to open an account.
Try our handy filter to find which one suits you best.

Compare accounts

Important Documents

There are no documents available for this stock.


Index: The Foxberry Medical Cannabis & Life Sciences USD Net Total Return Index (the “Index”) provides exposure to global publicly-traded companies which are involved in the global medical cannabis and cannabis related life sciences sectors, with a focus on companies in the biotechnology/pharma and hemp and cannabidiol (CBD) sectors, as determined by the Thematic Industry Expert (Tematica Research), but excluding companies that are considered to be either non-compliant with state and federal laws in the countries in which they operate and/or directly involved in the production and/or distribution of cannabis and/or cannabis-derived products containing more than hemp-defined levels of tetrahydrocannabinol (THC) for the recreational consumer market, as determined in accordance with the Rize Global Medical Cannabis Exclusion List Methodology. The Index rebalances semi-annually. All companies classified as Big Pharma (as defined in the Index Methodology) are given a group weight of 10% and the relevant companies are equally-weighted within that. All other companies are liquidity-weighted subject to a minimum weight per company of 0.05% and a maximum weight per company of 15%.
Aim: The investment objective of the Fund is to provide exposure to publicly-listed...
Read full aim for Rize ICAV
Leverage: 100%
Currency hedging: No


Ongoing Charge (OCF/TER): 0.65%
Management fee: 0.65%
Indicative spread: 0.55%

In certain cases, where no TER or OCF is shown, additional costs may apply. Please ensure you have read the Key Investor Information Document, Factsheet, Prospectus and any other relevant documentation prior to investing.


1 week 1W 0.9% 1 year 1Y n/a
1 month 1M 18.47% 2 years 2Y n/a
3 months 3M 20.29% 3 years 3Y n/a
6 months 6M n/a 5 years 5Y n/a

Performance figures are based on the previous close price. Past performance is not an indication of future performance.

Recent trade data is unavailable. We will be replacing it, however in the meantime the information is available on the London Stock Exchange website.

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Data provided by Funds Library. Some of the data on this page and other related pages is provided to you for your information and is received from the Fund Management Company administering this fund. Hargreaves Lansdown accepts no liability for the reliability or accuracy of the data provided by third parties. Securities lending data correct as at date not available. Charge data correct as at 31 March 2020. Holdings correct as at 31 May 2020.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.